Back to results
US 10,519,235 B2Granted
Anti-PD1 antibodies and their use as therapeutics and diagnostics
AssigneeBeiGene Switzerland GmbH
InventorsKang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
Life of this patent
Estimating the term…
Abstract
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Claims10
A monoclonal antibody which binds human PD-1, wherein the antibody suppresses PD-1 mediated signal transduction, comprising,
- a PD-1 binding domain, and
- an IgG4 Fc region comprising an amino acid mutation at position 228 and at least one additional amino acid mutation;
- wherein the at least one additional mutation causes the antibody to exhibit reduced binding to at least one Fcγ receptor relative to Fc binding of a reference IgG4 antibody having a mutation at position 228 and no other Fc region mutation;
- and
- wherein the numbering of the residues in the IgG4 Fc region is that of the EU numbering system.
2 more elements
Dependencies are inferred from the claim text.